Home » Newsletters » BioWorld Asia

BioWorld Asia

April 8, 1998

View Archived Issues

OGS In US$50M Pfizer Deal; Raises £31M In LSE Float

Natural Enzyme Activity May Improve Gene Therapy

Swedish, Danish Health Sectors Attract US$537M In Two Years

Lion Bioscience Reports Dynamic First-Year Operations

Biota's Flu Drug Submitted For Approval In Australia

Oxagen Raises £8M In Financing For Gene Identification Programs

Cambridge Antibody, Progenitor Team Up For Drug Discovery

Gemini, Affymetrix To Study Genetic Links To Osteoporosis

Biomira To Sell Diagnostics Subsidiary To Centocor

Agen Valued Higher Than Proposed Takeover Bid

Pharmos Gets 2 FDA Approvals; Eyes First Drug Revenues

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...